Royalty Pharma expects FY 2024 Portfolio Receipts ~$2.8B, at upper end of guidance

Royalty Pharma plc

2024-FY EPS reported $1.91 revenue$2,263,576,000

FY 2024 Portfolio Receipts expected ~$2,800M (upper end of $2,750-$2,800M range).
Underlying Royalty Receipts growth ~13% YoY; Adjusted EBITDA ~$2,560-2,570M.
Capital deployed $2.8B in 2024, record $925M synthetic royalty deals (Rytelo, Niktimvo, Yorvipath).
Late-stage pipeline potential peak royalties >$1.2B/yr; key catalysts: pelacarsen (Phase 3 2025), aficamten (PDUFA Sept 2025).
Announced acquisition of external manager and increased share repurchase commitment (details not provided in this release).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.